Jasper Therapeutics, Inc. (JSPR) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Jasper Therapeutics, Inc. (JSPR) Healthcare & Pipeline Overview

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on pioneering therapeutic agents for hematopoietic stem cell transplantation and gene therapies. Their lead product, JSP191, aims to improve stem cell therapy outcomes by clearing hematopoietic stem cells from bone marrow, positioning them within the evolving landscape of cell and gene therapy.

What Is the Investment Thesis for JSPR?

Jasper Therapeutics, Inc. presents a focused investment opportunity within the biotechnology sector, driven by its lead product candidate, JSP191. JSP191's clinical development as a conditioning antibody for hematopoietic stem cell transplantation and gene therapy represents a significant value driver. Successful clinical trials and subsequent regulatory approval could lead to substantial revenue generation. The company's focus on engineered hematopoietic stem cells further diversifies its pipeline and addresses limitations in current transplantation methods. However, the company's market capitalization of $11.4M reflects the inherent risks associated with clinical-stage biotechnology companies, including potential clinical trial failures, regulatory hurdles, and competition from established players. The company's beta of 3.20 indicates high volatility, requiring investors to carefully consider their risk tolerance. Upcoming clinical trial results for JSP191 will be a critical catalyst to watch.

Based on FMP financials and quantitative analysis

JSPR Key Highlights

Jasper Therapeutics is a clinical-stage biotechnology company focused on hematopoietic stem cell transplantation and gene therapies.

• The lead product candidate, JSP191, is in clinical development as a conditioning antibody.
• The company is developing engineered hematopoietic stem cell product candidates.
• Jasper Therapeutics is based in Redwood City, California.
• The company has a market capitalization of $11.4M and a beta of 3.20.

Who Are JSPR's Competitors?

JSPR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are JSPR's Key Strengths?

Innovative technology platform for stem cell engineering.

• Lead product candidate, JSP191, in clinical development.
• Experienced management team with expertise in biotechnology.
• Focus on a growing market with unmet medical needs.

What Are JSPR's Weaknesses?

Clinical-stage company with no currently approved products.

• Reliance on successful clinical trial outcomes.
• Limited financial resources compared to larger pharmaceutical companies.
• High cash burn rate associated with research and development.

What Could Drive JSPR Stock Higher?

Clinical trial results for JSP191 in stem cell transplantation.

• Regulatory submissions for JSP191.
• Development of engineered hematopoietic stem cell product candidates.
• Strategic partnerships and collaborations.

What Are the Key Risks for JSPR?

Listing risk — at $0.704 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.

• Financial-distress signal — its Altman Z-Score of -45.88 sits in the distress zone (elevated bankruptcy risk).
• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Clinical trial failures for JSP191.
• Regulatory delays or non-approval of JSP191.
• Competition from established pharmaceutical companies.
• High cash burn rate and need for additional financing.
• Dependence on key personnel and intellectual property.

What Are the Growth Opportunities for JSPR?

• Expansion of JSP191 into New Indications: Jasper Therapeutics has the opportunity to expand the use of JSP191 beyond its current clinical focus. Exploring its application in other hematological malignancies or autoimmune diseases could significantly broaden its market potential. The market for conditioning agents in stem cell transplantation is estimated to grow as stem cell therapies become more prevalent. This expansion could occur within the next 3-5 years, contingent on successful clinical trials and regulatory approvals.
• Development of Engineered Hematopoietic Stem Cells: The company's efforts to develop engineered hematopoietic stem cells represent a significant growth opportunity. These engineered cells could overcome limitations of allogeneic and autologous gene-edited stem cell grafts, potentially leading to more successful transplantation outcomes. The market for gene-edited cell therapies is rapidly expanding, driven by advancements in gene editing technologies. This development could materialize in the next 5-7 years, pending further research and clinical validation.
• Strategic Partnerships and Collaborations: Jasper Therapeutics can pursue strategic partnerships and collaborations with other biotechnology companies or academic institutions to accelerate the development and commercialization of its product candidates. Collaborations can provide access to new technologies, funding, and expertise. The biotechnology industry is characterized by numerous partnerships aimed at sharing resources and mitigating risks. Such partnerships could be established within the next 1-2 years.
• Geographic Expansion: Jasper Therapeutics has the opportunity to expand its geographic reach beyond the United States. Entering European or Asian markets could significantly increase its potential customer base. The global market for stem cell transplantation is growing, with increasing demand in emerging economies. This expansion could occur in the next 3-5 years, contingent on regulatory approvals and market access strategies.
• Advancements in Manufacturing Processes: Improving the efficiency and scalability of its manufacturing processes can reduce costs and increase the availability of its products. Investing in advanced manufacturing technologies can provide a competitive advantage. The biotechnology industry is constantly seeking ways to optimize manufacturing processes to improve profitability. These advancements could be implemented within the next 2-3 years.

What Are JSPR's Competitive Advantages?

• Proprietary technology and intellectual property related to JSP191 and engineered stem cells.
• Clinical data supporting the safety and efficacy of its product candidates.
• Expertise in stem cell biology and transplantation.
• Strong relationships with key opinion leaders in the field.

What Does JSPR Do?

Jasper Therapeutics, Inc., established to advance the field of stem cell transplantation and gene therapy, is a clinical-stage biotechnology company dedicated to developing innovative therapeutic solutions. The company's primary focus is on overcoming the limitations associated with hematopoietic stem cell transplantation, a procedure used to treat various blood cancers and genetic disorders. Jasper Therapeutics is headquartered in Redwood City, California. Their lead product candidate, JSP191, is a conditioning antibody designed to clear hematopoietic stem cells from the bone marrow of patients before they undergo allogeneic stem cell therapy or stem cell gene therapy. This conditioning process is crucial for creating space in the bone marrow, allowing the transplanted or gene-modified stem cells to engraft and proliferate. In addition to JSP191, Jasper Therapeutics is developing engineered hematopoietic stem cell product candidates. These engineered cells are designed to address the challenges of graft rejection and improve the overall success of stem cell transplantation. The company's research and development efforts are centered on expanding the accessibility and efficacy of stem cell transplantation and ex vivo gene therapy, a technique involving the genetic manipulation of cells outside the body before transplantation. By focusing on both conditioning agents and stem cell engineering, Jasper Therapeutics aims to provide comprehensive solutions for patients in need of stem cell-based therapies.

What Products and Services Does JSPR Offer?

• Develops therapeutic agents for hematopoietic stem cell transplantation.
• Focuses on conditioning agents to prepare patients for stem cell therapy.
• Engineers stem cells to improve transplantation outcomes.
• Conducts clinical trials to evaluate the safety and efficacy of its products.
• Aims to expand the use of stem cell transplantation and gene therapy.
• Develops JSP191, a conditioning antibody in clinical development.

How Does JSPR Make Money?

• Develops and patents therapeutic agents for stem cell transplantation and gene therapy.
• Outlicenses or partners with larger pharmaceutical companies for commercialization.
• Generates revenue through licensing agreements, milestone payments, and royalties.
• Focuses on research and development to create innovative products.

What Industry Does JSPR Operate In?

Jasper Therapeutics operates within the biotechnology industry, specifically targeting the hematopoietic stem cell transplantation and gene therapy market. This market is driven by the increasing prevalence of blood cancers, genetic disorders, and the growing demand for personalized medicine. The competitive landscape includes established pharmaceutical companies and other biotechnology firms developing similar therapies. Jasper Therapeutics aims to differentiate itself through its focus on conditioning agents and stem cell engineering, seeking to improve the safety and efficacy of stem cell transplantation. The biotechnology industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition.

Who Are JSPR's Key Customers?

• Hospitals and transplant centers that perform stem cell transplantations.
• Patients with blood cancers and genetic disorders who require stem cell therapy.
• Pharmaceutical companies that license or partner with Jasper Therapeutics.
• Research institutions and academic centers involved in stem cell research.

Jasper Therapeutics, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -45.88 places it in the distress zone, a signal of elevated financial risk.

Jasper Therapeutics, Inc. (JSPR) Valuation Context

Valued at $11.4M, JSPR is classified as a micro-cap stock. Analyst price targets span from $2.00 to $3.00, with a consensus of $2.50. At the current price of $0.70, that implies approximately 255% upside potential. Relative to its peer group, JSPR's quantitative score of 29/100 is below the peer average of 78/100.

Company Profile

Jasper Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Redwood City, US. The company is led by CEO Jeetinder Singh Mahal. JSPR has traded publicly since 2020.

Jasper Therapeutics, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 11.8% above estimates on average.

Wall Street analysts project Jasper Therapeutics, Inc. revenue of about $12.0M for fiscal 2026, with EPS near $-0.67. The estimate reflects 5 contributing analysts.

Over the past six months, Jasper Therapeutics, Inc. insiders filed 8 SEC Form 4 transactions — 0 sales and 8 purchases. On net that is roughly 54K shares acquired (about $35K) — insiders putting money in tends to read as conviction.

JSPR Financials

JSPR Latest News

JSPR Analyst Consensus

JSPR MoonshotScore

What Investors Ask About Jasper Therapeutics, Inc. (JSPR) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources